Leerink Partners Reiterates Outperform on 4D Molecular Therapeutics, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has reiterated its Outperform rating for 4D Molecular Therapeutics (NASDAQ:FDMT) but lowered the price target from $40 to $36.
September 19, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Leerink Partners has reiterated its Outperform rating for 4D Molecular Therapeutics but lowered the price target from $40 to $36, indicating a slightly less optimistic outlook.
The reiteration of the Outperform rating suggests continued confidence in FDMT's potential, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100